Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2018, Article ID 4248971, 10 pages
https://doi.org/10.1155/2018/4248971
Research Article

RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients

1Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
2Beijing Novogene Bioinformatics Technology Co., Ltd., Beijing, China
3Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
4Department of Pathology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Correspondence should be addressed to Mulan Jin; moc.361@narukomnik, Gang Cheng; moc.enegovon@gnehc.ffej, and Guangyu An; moc.liamtoh@uygnaugna

Received 8 November 2017; Accepted 31 January 2018; Published 7 March 2018

Academic Editor: Kiran L. Sharma

Copyright © 2018 Jiannan Yao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2014. View at Publisher · View at Google Scholar
  2. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, and J. Lortet-Tieulent, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar
  3. R. G. Amado, M. Wolf, M. Peeters et al., “Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1626–1634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Bokemeyer, I. Bondarenko, J. T. Hartmann et al., “Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study,” Annals of Oncology, vol. 22, no. 7, pp. 1535–1546, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Y. Douillard, K. S. Oliner, and S. Siena, “Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer,” The New England Journal of Medicine, vol. 369, no. 11, pp. 1023–1034, 2013. View at Publisher · View at Google Scholar
  6. E. Van Cutsem, A. Cervantes, and R. Adam, “ESMO consensus guidelines for the management of patients with metastatic colorectal cancer,” Annals of Oncology, vol. 27, no. 8, pp. 1386–1422, 2016. View at Publisher · View at Google Scholar
  7. D. Lee, K. J. Kim, S. Han et al., “KRAS Mutation is Associated with Worse Prognosis in Stage III or High-risk Stage II Colon Cancer Patients Treated with Adjuvant FOLFOX,” Annals of Surgical Oncology, vol. 22, no. 1, pp. 187–194, 2015. View at Publisher · View at Google Scholar
  8. D. P. Modest, I. Ricard, V. Heinemann et al., “Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: Pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group,” Annals of Oncology, vol. 27, no. 9, Article ID mdw261, pp. 1746–1753, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. C.-W. Huang, H.-L. Tsai, Y.-T. Chen et al., “The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer,” BMC Cancer, vol. 13, article 599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Mariani, M. Lae, A. Degeorges, W. Cacheux, E. Lappartient, A. Margogne et al., “Concordant Analysis of KRAS Status in Primary Colon Carcinoma and Matched Metastasis,” Anticancer Res, vol. 30, no. 10, pp. 4229–4235, 2010. View at Google Scholar
  11. D. Santini, F. Loupakis, B. Vincenzi et al., “High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice,” The Oncologist, vol. 13, no. 12, pp. 1270–1275, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Wan, Z. Wang, J. J. Lee et al., “Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer,” Journal of Thoracic Oncology, vol. 12, no. 9, pp. 1376–1387, 2017. View at Publisher · View at Google Scholar
  13. M. J. Overman, J-N. Vauthey, T. A. Aloia, C. Conrad, Y. S. Chun, and A. A. L. Pereira, “Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence,” Journal of Clinical Oncology, vol. 35, supplement 3522, no. 15, 2017. View at Google Scholar
  14. F. Pietrantonio, F. Petrelli, A. Coinu et al., “Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis,” European Journal of Cancer, vol. 51, no. 5, article no. 9390, pp. 587–594, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Yaeger, A. Cercek, J. F. Chou et al., “BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer,” Cancer, vol. 120, no. 15, pp. 2316–2324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Di Nicolantonio, M. Martini, F. Molinari et al., “Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 26, no. 35, pp. 5705–5712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. W. S. Samowitz, C. Sweeney, J. Herrick, H. Albertsen, T. R. Levin, and M. A. Murtaugh, “Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon Cancers,” Cancer Research, vol. 65, no. 14, 2005. View at Google Scholar
  18. M. J. Sorich, M. D. Wiese, A. Rowland, G. Kichenadasse, R. A. McKinnon, and C. S. Karapetis, “Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials,” Annals of Oncology, vol. 26, no. 1, pp. 13–21, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Akishima-Fukasawa, Y. Ishikawa, Y. Akasaka et al., “Histopathological predictors of regional lymph node metastasis at the invasive front in early colorectal cancer,” Histopathology, vol. 59, no. 3, pp. 470–481, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. E. D. Courtney, N. J. West, C. Kaur et al., “Extramural vascular invasion is an adverse prognostic indicator of survival in patients with colorectal cancer,” Colorectal Disease, vol. 11, no. 2, pp. 150–156, 2009. View at Publisher · View at Google Scholar
  21. T. Sugai, N. Yamada, M. Eizuka et al., “Vascular Invasion and Stromal S100A4 Expression at the Invasive Front of Colorectal Cancer are Novel Determinants and Tumor Prognostic Markers,” Journal of Cancer, vol. 8, no. 9, pp. 1552–1561, 2017. View at Publisher · View at Google Scholar
  22. J. Vidal, L. Muinelo, A. Dalmases et al., “Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients,” Annals of Oncology, vol. 28, no. 6, Article ID mdx125, pp. 1325–1332, 2017. View at Publisher · View at Google Scholar · View at Scopus